Modeling biomarker kinetics of Aβ levels in serum following blast
Elucidating the unique neuropathological response to blast exposure remains a barrier towards the development of diagnostic approaches for those with blast-induced traumatic brain injury (bTBI). Quantification of biomarker concentrations in the blood post-injury is typically used to inform brain inj...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-04-01
|
| Series: | Frontiers in Neurology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fneur.2025.1548589/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849735605432352768 |
|---|---|
| author | Carly Norris Harsha T. Garimella Walter Carr Angela M. Boutté Raj K. Gupta Andrzej J. Przekwas |
| author_facet | Carly Norris Harsha T. Garimella Walter Carr Angela M. Boutté Raj K. Gupta Andrzej J. Przekwas |
| author_sort | Carly Norris |
| collection | DOAJ |
| description | Elucidating the unique neuropathological response to blast exposure remains a barrier towards the development of diagnostic approaches for those with blast-induced traumatic brain injury (bTBI). Quantification of biomarker concentrations in the blood post-injury is typically used to inform brain injury severity. However, injury progression and associated changes in biomarker concentrations are sensitive to parameters such as the blast overpressure (BOP) magnitude and frequency of blast exposure. Through this work, a blast-dose biomarker kinetics (BxK) platform was developed and validated for Aβ42 as a promising predictor of injury post-blast. Blast-dose responses accounting for BOP magnitude and frequency were integrated into a mathematical model accounting for whole-body Aβ peptide kinetics. Validation of the developed model was performed through comparison with acute monomer levels in the blood serum of 15 service members exposed to repeated low-level blast while undergoing three-day weapons training. Amyloid precursor protein (APP) synthesis was assumed to be proportional to blast magnitude and additive effects within a window of recovery were applied to account for cumulative exposure. Aβ42 concentrations in the blood serum were predicted within 6.5 ± 5.2% on average, demonstrating model feasibility and biomarker sensitivity to blast. Outcomes discuss how modulation of patient-specific factors (age, weight, genetic factors, years of exposure, sleep) and pathophysiological factors (BBB permeability, amyloidogenic pathology, neuroinflammation) can reveal potential sources of variability in experimental data and be incorporated into the blast-dose BxK platform in future iterations. Advancements in model complexity accounting for sex-specific factors, weapon system, stress levels, risk of symptom onset, and pharmacological treatment strategies are anticipated to improve model calibration. Utilization of this blast-dose BxK model to identify drivers of pathophysiological mechanisms and predict chronic outcomes has the potential to transform bTBI diagnostic, prognostic, and therapeutic strategies. |
| format | Article |
| id | doaj-art-369d8d22d74c4d3aaa6a673170816910 |
| institution | DOAJ |
| issn | 1664-2295 |
| language | English |
| publishDate | 2025-04-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Neurology |
| spelling | doaj-art-369d8d22d74c4d3aaa6a6731708169102025-08-20T03:07:32ZengFrontiers Media S.A.Frontiers in Neurology1664-22952025-04-011610.3389/fneur.2025.15485891548589Modeling biomarker kinetics of Aβ levels in serum following blastCarly Norris0Harsha T. Garimella1Walter Carr2Angela M. Boutté3Raj K. Gupta4Andrzej J. Przekwas5Biomedical, Energy, and Materials Division, CFD Research Corporation, Huntsville, AL, United StatesBiomedical, Energy, and Materials Division, CFD Research Corporation, Huntsville, AL, United StatesBlast-Induced Neurotrauma Branch, Center for Military Psychiatry and Neuroscience, Walter Reed Army Institute of Research (WRAIR), Silver Spring, MD, United StatesBlast-Induced Neurotrauma Branch, Center for Military Psychiatry and Neuroscience, Walter Reed Army Institute of Research (WRAIR), Silver Spring, MD, United StatesUS Army Medical Research and Development Command, DoD Blast Injury Research Coordinating Office (BIRCO), Fort Detrick, MD, United StatesBiomedical, Energy, and Materials Division, CFD Research Corporation, Huntsville, AL, United StatesElucidating the unique neuropathological response to blast exposure remains a barrier towards the development of diagnostic approaches for those with blast-induced traumatic brain injury (bTBI). Quantification of biomarker concentrations in the blood post-injury is typically used to inform brain injury severity. However, injury progression and associated changes in biomarker concentrations are sensitive to parameters such as the blast overpressure (BOP) magnitude and frequency of blast exposure. Through this work, a blast-dose biomarker kinetics (BxK) platform was developed and validated for Aβ42 as a promising predictor of injury post-blast. Blast-dose responses accounting for BOP magnitude and frequency were integrated into a mathematical model accounting for whole-body Aβ peptide kinetics. Validation of the developed model was performed through comparison with acute monomer levels in the blood serum of 15 service members exposed to repeated low-level blast while undergoing three-day weapons training. Amyloid precursor protein (APP) synthesis was assumed to be proportional to blast magnitude and additive effects within a window of recovery were applied to account for cumulative exposure. Aβ42 concentrations in the blood serum were predicted within 6.5 ± 5.2% on average, demonstrating model feasibility and biomarker sensitivity to blast. Outcomes discuss how modulation of patient-specific factors (age, weight, genetic factors, years of exposure, sleep) and pathophysiological factors (BBB permeability, amyloidogenic pathology, neuroinflammation) can reveal potential sources of variability in experimental data and be incorporated into the blast-dose BxK platform in future iterations. Advancements in model complexity accounting for sex-specific factors, weapon system, stress levels, risk of symptom onset, and pharmacological treatment strategies are anticipated to improve model calibration. Utilization of this blast-dose BxK model to identify drivers of pathophysiological mechanisms and predict chronic outcomes has the potential to transform bTBI diagnostic, prognostic, and therapeutic strategies.https://www.frontiersin.org/articles/10.3389/fneur.2025.1548589/fullAβ42diagnosticsblastbrainbiomarkerserum |
| spellingShingle | Carly Norris Harsha T. Garimella Walter Carr Angela M. Boutté Raj K. Gupta Andrzej J. Przekwas Modeling biomarker kinetics of Aβ levels in serum following blast Frontiers in Neurology Aβ42 diagnostics blast brain biomarker serum |
| title | Modeling biomarker kinetics of Aβ levels in serum following blast |
| title_full | Modeling biomarker kinetics of Aβ levels in serum following blast |
| title_fullStr | Modeling biomarker kinetics of Aβ levels in serum following blast |
| title_full_unstemmed | Modeling biomarker kinetics of Aβ levels in serum following blast |
| title_short | Modeling biomarker kinetics of Aβ levels in serum following blast |
| title_sort | modeling biomarker kinetics of aβ levels in serum following blast |
| topic | Aβ42 diagnostics blast brain biomarker serum |
| url | https://www.frontiersin.org/articles/10.3389/fneur.2025.1548589/full |
| work_keys_str_mv | AT carlynorris modelingbiomarkerkineticsofablevelsinserumfollowingblast AT harshatgarimella modelingbiomarkerkineticsofablevelsinserumfollowingblast AT waltercarr modelingbiomarkerkineticsofablevelsinserumfollowingblast AT angelamboutte modelingbiomarkerkineticsofablevelsinserumfollowingblast AT rajkgupta modelingbiomarkerkineticsofablevelsinserumfollowingblast AT andrzejjprzekwas modelingbiomarkerkineticsofablevelsinserumfollowingblast |